HDM1005 2

DRUG4 trials

Sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Obesity & OverweightType 2 Diabetes

Phase 2

A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

RecruitingNCT07109700

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2025-04-30End: 2026-02-28Target: 216Updated: 2025-08-17

Phase 3

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

RecruitingNCT07279194

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Obesity & Overweight

Start: 2025-10-14End: 2026-12-13Target: 825Updated: 2025-12-12

A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

RecruitingNCT07394114

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2026-02-24End: 2027-12-17Target: 240Updated: 2026-02-09

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Not yet recruitingNCT07417306

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2026-03-27End: 2027-12-31Target: 912Updated: 2026-02-18